BioCentury
ARTICLE | Clinical News

Lilly's ramucirumab meets OS endpoint in gastric cancer

October 16, 2012 1:33 AM UTC

Eli Lilly and Co. (NYSE:LLY) said ramucirumab met the primary endpoint in the Phase III REGARD trial to treat metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum or fluoropyrimidine-containing combination therapy. Ramucirumab given every two weeks plus best supportive care significantly improved overall survival vs. best supportive care alone. The human IgG1 mAb VEGFR-2 antagonist also met the secondary endpoint of improving progression-free survival (PFS). The trial enrolled 355 patients. Lilly plans to present the REGARD data at an upcoming scientific meeting and will discuss submission plans with regulatory authorities. ...